Added to YB: 2026-02-10
Pitch date: 2026-02-06
NOVO-B.CO [neutral]
Novo Nordisk A/S
-12.99%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 302.78
Price Target
571.22 (+117%)
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
value
Novo Nordisk is Crashing after Earnings
NOVO-B.CO (earnings): Q4 showed 10% sales growth but -17% stock drop on 2026 guidance of -5% to -13% sales/profit decline due to US pricing pressure, patent expiries, competition. Obesity care +31%, oral Wegovy launched. Trading at discount despite long-term GLP-1 dominance. Fair value DKK 571 vs DKK 303 (+88% upside).
Read full article (4 min)